PMVP Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03

Price $1.79

Market Cap (MRQ) $96M

P/E -1.2

EPS $-1.48

ROE -63.4%

52W Range $1–$2

PMVP Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04

range

bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

10-Year Performance Revenue, net income, margins and EPS trends

06

EPS$-1.48

2020-12-31 → 2025-12-31

Free Cash Flow$-74M

2020-12-31 → 2025-12-31

Net margin-1226.8%

2020-12-31 → 2025-12-31

Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric	PMVP	5Y avg	Peer Median	Verdict
P/E	-1.25Y avg ≈-5.6	≈-5.6	·	·
P/S	15.15Y avg ≈495.9	≈495.9	73.7	Undervalued
P/B (MRQ)	1.35Y avg ≈1.4	≈1.4	2.5	Undervalued
Price / FCF (TTM)	-1.35Y avg ≈-6.5	≈-6.5	·	·
Price / Cash Flow (TTM)	-1.35Y avg ≈-6.8	≈-6.8	·	·
Price / Tangible Book	0.95Y avg ≈1.4	≈1.4	·	·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric	PMVP	5Y avg	Peer Median	Verdict
Operating Margin	-1360.4%5Y avg ≈-3597.3%	≈-3597.3%	-3199.0%	Top tier
EBITDA Margin	-1360.4%5Y avg ≈-3597.3%	≈-3597.3%	-3199.0%	Top tier
Pretax Margin	-1261.1%5Y avg ≈-3496.1%	≈-3496.1%	-2294.8%	In line
Net Profit Margin	-1226.8%5Y avg ≈-3460.0%	≈-3460.0%	-2452.9%	In line
ROA	-50.5%5Y avg ≈-28.9%	≈-28.9%	-57.6%	In line
ROE	-63.4%5Y avg ≈-34.3%	≈-34.3%	-63.4%	In line
ROIC	-80.1%5Y avg ≈-40.8%	≈-40.8%	-68.6%	Below avg

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric	5Y trend	PMVP	5Y avg	Peer Median	Verdict
Current Ratio (MRQ)		7.75Y avg ≈16.9	≈16.9	7.7	In line
Quick Ratio		9.95Y avg ≈16.5	≈16.5	7.5	In line

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric	PMVP	5Y avg	Peer Median	Verdict
Revenue YoY	-40.5%5Y avg ≈167.9%	≈167.9%	·	·
Revenue CAGR 3Y	20.4%5Y avg ≈121.9%	≈121.9%	·	·
Revenue CAGR 5Y	57.6%	·	·	·

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric	PMVP	5Y avg	Peer Median	Verdict
EPS (Diluted)	$-1.485Y avg ≈$-1.39	≈$-1.39	·	·
Revenue / Share	$0.125Y avg ≈$0.16	≈$0.16	·	·
Cash Flow / Share	$-1.405Y avg ≈$-1.24	≈$-1.24	·	·
Cash / Share	$0.715Y avg ≈$1.68	≈$1.68	·	·

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric	5Y trend	PMVP	5Y avg	Peer Median	Verdict
Asset Turnover		0.05Y avg ≈0.0	≈0.0	0.0	Top tier

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14

Avg Surprise 9.8%

Next Report Nov 10, 2026

Period	Report	EPS Actual	EPS Est	Surprise
June 30, 2026	Aug 14, 2026	$-0.34	$-0.40	14.0%
March 31, 2026	May 8, 2026	$-0.34	$-0.42	18.7%
Dec. 31, 2025		$-0.34	$-0.41	17.7%
Sept. 30, 2025		$-0.40	$-0.41	2.6%
June 30, 2025		$-0.41	$-0.39	-4.9%
March 31, 2025		$-0.34	$-0.38	11.0%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15

Income Statement 13

Metric	2025	2024	2023	2022	2021	2020	2019
R&D Expense	$70M	$59M	$56M	$52M	$36M	$24M	$21M
SG&A Expense	$16M	$27M	$24M	$25M	$22M	$11M	$6M
Operating Expenses	$86M	$85M	$80M	$77M	$58M	$35M	$27M
Operating Income	$-86M	$-85M	$-80M	$-77M	$-58M	$-35M	$-27M
Other Non-op	$6M	$11M	$11M	$4M	$470.0K	$508.0K	$1M
Pretax Income	$-80M	$-75M	$-69M	$-73M	$-58M	$-34M	$-25M
Income Tax	$-2M	$-16M	$2.0K	$-9.0K	$23.0K	$6.0K	$8.0K
Net Income	$-78M	$-59M	$-69M	$-73M	$-58M	$-34M	$-25M
EPS (Basic)	$-1.48	$-1.14	$-1.44	$-1.61	$-1.28	$-2.40	·
EPS (Diluted)	$-1.48	$-1.14	$-1.44	$-1.61	$-1.28	$-2.40	·
Shares (Basic)	52,541,613	51,578,807	48,014,645	45,594,824	45,137,656	14,364,475	·
Shares (Diluted)	52,541,613	51,578,807	48,014,645	45,594,824	45,137,656	14,364,475	·
EBITDA	$-86M	$-85M	$-80M	$-77M	$-58M	$-35M	·

Balance Sheet 20

Metric	2025	2024	2023	2022	2021	2020	2019
Cash & Equivalents	$38M	$41M	$38M	$108M	$172M	$361M	$73M
Short-term Investments	$75M	$129M	$165M	$133M	$125M	·	·
Prepaid Expense	$2M	$6M	$4M	$5M	$3M	$3M	$607.0K
Current Assets	$115M	$176M	$207M	$247M	$301M	$365M	$102M
PP&E (Net)	$237.0K	$409.0K	$11M	$11M	$3M	$569.0K	$739.0K
PP&E (Gross)	$2M	$2M	$14M	$13M	$5M	$2M	$2M
Accum. Depreciation	$1M	$1M	$3M	$2M	$2M	$2M	$1M
Other Non-current Assets	$297.0K	$235.0K	$190.0K	$313.0K	$221.0K	$201.0K	$201.0K
Total Assets	$117M	$191M	$252M	$270M	$332M	$366M	$103M
Accounts Payable	$3M	$7M	$3M	$3M	$3M	$2M	$3M
Accrued Liabilities	$8M	$7M	$10M	$7M	$9M	$5M	$2M
Current Liabilities	$11M	$14M	$14M	$11M	$12M	$6M	$5M
Capital Leases	$435.0K	$838.0K	$12M	$13M	$11M	·	·
Other Non-current Liabilities	·	·	·	·	·	·	$51.0K
Total Liabilities	$12M	$15M	$26M	$24M	$23M	$6M	$5M
Retained Earnings	$-446M	$-369M	$-310M	$-241M	$-168M	$-110M	$-75M
AOCI	$84.0K	$139.0K	$224.0K	$-445.0K	$-78.0K	·	$-3.0K
Stockholders' Equity	$105M	$176M	$226M	$246M	$309M	$359M	$-70M
Liabilities + Equity	$117M	$191M	$252M	$270M	$332M	$366M	$103M
Shares Outstanding	53,331,766	51,935,134	51,445,862	45,771,332	45,433,684	44,777,818	3,046,200

Cash Flow 10

Metric	2025	2024	2023	2022	2021	2020	2019
Stock-based Comp	$6M	$9M	$12M	$10M	$5M	$2M	$908.0K
Operating Cash Flow	$-74M	$-51M	$-56M	$-64M	$-47M	$-33M	$-22M
CapEx	$29.0K	$655.0K	$962.0K	$8M	$1M	$148.0K	$109.0K
Investing Cash Flow	$70M	$53M	$-51M	$-1M	$-144M	$28M	$3M
Stock Issued	·	·	$35M	·	·	$223M	·
Net Stock Activity	·	·	$35M	·	·	$223M	·
Financing Cash Flow	$505.0K	$313.0K	$36M	$958.0K	$2M	$293M	$62M
Net Change in Cash	$-3M	$2M	$-71M	$-64M	$-188M	$288M	$43M
Taxes Paid	·	·	·	·	$23.0K	$6.0K	$8.0K
Free Cash Flow	$-74M	$-52M	$-57M	$-72M	$-48M	$-33M	·

Profitability 7

Metric	2025	2024	2023	2022	2021	2020	2019
Operating Margin	-1360.4%	-802.0%	-717.3%	-2124.1%	-12982.8%	-5367.4%	·
Net Margin	-1226.8%	-551.0%	-617.3%	-2021.4%	-12883.3%	-5290.3%	·
Pretax Margin	-1261.1%	-702.1%	-617.3%	-2021.7%	-12878.2%	-5289.4%	·
EBITDA Margin	-1360.4%	-802.0%	-717.3%	-2124.1%	-12982.8%	-5367.4%	·
ROA	-50.5%	-26.5%	-26.4%	-24.4%	-16.6%	-14.7%	·
ROE	-63.4%	-31.4%	-29.8%	-28.9%	-18.3%	-9.5%	·
ROIC	-80.1%	-38.1%	-35.5%	-31.3%	-18.9%	-9.7%	·

Liquidity & Solvency 2

Metric	Trend	2025	2024	2023	2022	2021	2020	2019
Current Ratio		10.1	12.2	14.8	22.8	24.7	56.9	·
Quick Ratio		9.9	11.8	14.5	22.3	24.3	56.4	·

Efficiency 1

Metric	Trend	2025	2024	2023	2022	2021	2020	2019
Asset Turnover		0.0	0.0	0.0	0.0	0.0	0.0	·

Per Share 5

Metric	2025	2024	2023	2022	2021	2020	2019
Book Value / Share	$1.96	$3.39	$4.39	$5.38	$6.79	$8.02	·
Revenue / Share	$0.12	$0.21	$0.23	$0.08	·	·	·
Cash Flow / Share	$-1.40	$-0.99	$-1.16	$-1.40	·	·	·
Cash / Share	$0.71	$0.79	$0.73	$2.37	$3.80	$8.07	·
EPS (TTM)	$-1.48	$-1.14	$-1.44	$-1.61	$-1.28	$-2.40	·

Growth Rates 3

Metric	2025	2024	2023	2022	2021	2020	2019
Revenue YoY	-40.5%	-4.6%	208.0%	707.8%	-31.0%	·	·
Revenue CAGR 3Y	20.4%	187.4%	157.9%	·	·	·	·
Revenue CAGR 5Y	57.6%	·	·	·	·	·	·

Valuation (TTM) 10

Metric	2025	2024	2023	2022	2021	2020	2019
Revenue TTM	$6M	$11M	$11M	$4M	$449.0K	$651.0K	·
Net Income TTM	$-78M	$-59M	$-69M	$-73M	$-58M	$-34M	·
Market Cap	$67M	$78M	$159M	$398M	$1.05B	$2.75B	·
P/E	-0.8	-1.3	-2.2	-5.4	-18.0	-25.6	·
P/S	10.5	7.4	14.3	109.8	2337.5	4230.9	·
P/B	0.6	0.4	0.7	1.6	3.4	7.7	·
P / Tangible Book	0.6	0.4	0.7	1.6	3.4	7.7	·
P / Cash Flow	-0.9	-1.5	-2.9	-6.2	-22.5	-84.1	·
P / FCF	-0.9	-1.5	-2.8	-5.6	-21.9	-83.7	·
Earnings Yield	-118.4%	-75.5%	-46.5%	-18.5%	-5.5%	-3.9%	·

Income Statement 13

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022
R&D Expense	$15M	$15M	$16M	$18M	$18M	$17M	$14M	$17M	$15M	$13M	$14M	$14M	$15M	$14M	$11M	$12M
SG&A Expense	$4M	$4M	$3M	$4M	$4M	$4M	$11M	$5M	$6M	$5M	$6M	$6M	$6M	$6M	$6M	$7M
Operating Expenses	$19M	$19M	$19M	$23M	$23M	$22M	$25M	$22M	$20M	$18M	$20M	$20M	$21M	$19M	$18M	$19M
Operating Income	$-19M	$-19M	$-19M	$-23M	$-23M	$-22M	$-25M	$-22M	$-20M	$-18M	$-20M	$-20M	$-21M	$-19M	$-18M	$-19M
Other Non-op	$798.0K	$981.0K	$1M	$1M	$2M	$2M	$2M	$3M	$3M	$3M	$3M	$3M	$2M	$1M	$573.0K	$188.0K
Pretax Income	$-18M	$-18M	$-18M	$-21M	$-21M	$-20M	$-23M	$-19M	$-17M	$-15M	$-17M	$-17M	$-19M	$-18M	$-17M	$-18M
Income Tax	$3.0K	·	$26.0K	$-6.0K	$5.0K	$-2M	$0	$74.0K	$-16M	·	$-1.0K	$4.0K	·	$-9.0K	$-2.0K	$2.0K
Net Income	$-18M	$-18M	$-18M	$-21M	$-21M	$-17M	$-23M	$-19M	$-1M	$-15M	$-17M	$-17M	$-19M	$-18M	$-17M	$-18M
EPS (Basic)	$-0.34	$-0.34	$-0.33	$-0.40	$-0.41	$-0.34	$-0.45	$-0.37	$-0.02	$-0.30	$-0.34	$-0.38	$-0.42	$-0.40	$-0.38	$-0.41
EPS (Diluted)	$-0.34	$-0.34	$-0.33	$-0.40	$-0.41	$-0.34	$-0.45	$-0.37	$-0.02	$-0.30	$-0.34	$-0.38	$-0.42	$-0.40	$-0.38	$-0.41
Shares (Basic)	53,386,909	53,331,766	·	52,993,238	52,010,827	51,952,062	·	51,574,027	51,478,751	51,445,862	49,047,296	45,813,132	45,773,357	45,622,957	45,571,067	45,466,044
Shares (Diluted)	53,386,909	53,331,766	·	52,993,238	52,010,827	51,952,062	·	51,574,027	51,478,751	51,445,862	49,047,296	45,813,132	45,773,357	45,622,957	45,571,067	45,466,044
EBITDA	$-19M	$-19M	·	$-23M	$-23M	$-22M	·	$-22M	$-20M	$-18M	$-20M	$-20M	$-21M	$-19M	$-18M	$-19M

Balance Sheet 19

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022
Cash & Equivalents	$12M	$39M	$38M	$36M	$44M	$51M	$41M	$49M	$49M	$48M	$52M	$68M	$143M	$100M	$87M	$116M
Short-term Investments	$67M	$54M	$75M	$93M	$98M	$109M	$129M	$134M	$164M	$150M	$150M	$119M	$86M	$159M	$190M	$167M
Prepaid Expense	$2M	$2M	$2M	$3M	$3M	$3M	$6M	$6M	$5M	$4M	$3M	$3M	$3M	$5M	$4M	$4M
Current Assets	$81M	$96M	$115M	$132M	$145M	$163M	$176M	$190M	$219M	$202M	$205M	$190M	$233M	$265M	$282M	$288M
PP&E (Net)	$154.0K	$203.0K	$237.0K	$255.0K	$287.0K	$376.0K	$409.0K	$10M	$11M	$11M	$11M	$11M	$11M	$10M	$9M	$5M
PP&E (Gross)	$2M	$2M	$2M	$2M	$2M	$2M	$2M	$14M	$15M	$15M	$14M	$14M	$14M	$12M	$11M	$7M
Accum. Depreciation	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$4M	$4M	$4M	$3M	$3M	$2M	$2M	$2M	$2M
Other Non-current Assets	$296.0K	$296.0K	$297.0K	$249.0K	$248.0K	$237.0K	$235.0K	$242.0K	$182.0K	$182.0K	$180.0K	$181.0K	$314.0K	$307.0K	$308.0K	$221.0K
Total Assets	$82M	$97M	$117M	$134M	$153M	$171M	$191M	$223M	$238M	$237M	$261M	$242M	$254M	$285M	$301M	$315M
Accounts Payable	$2M	$2M	$3M	$3M	$3M	$4M	$7M	$2M	$5M	$859.0K	$2M	$3M	$2M	$5M	$3M	$5M
Accrued Liabilities	$8M	$7M	$8M	$9M	$9M	$6M	$7M	$10M	$6M	$10M	$9M	$8M	$9M	$6M	$8M	$7M
Current Liabilities	$11M	$9M	$11M	$12M	$12M	$10M	$14M	$14M	$11M	$12M	$11M	$11M	$11M	$12M	$11M	$12M
Capital Leases	$0	$0	$435.0K	$541.0K	$643.0K	$742.0K	$838.0K	$12M	$12M	$12M	$13M	$13M	$13M	$12M	$12M	$11M
Total Liabilities	$11M	$9M	$12M	$13M	$12M	$11M	$15M	$26M	$23M	$24M	$23M	$24M	$24M	$24M	$24M	$23M
Retained Earnings	$-483M	$-464M	$-446M	$-428M	$-407M	$-386M	$-369M	$-346M	$-326M	$-325M	$-294M	$-278M	$-260M	$-222M	$-203M	$-186M
AOCI	$-82.0K	$-15.0K	$84.0K	$91.0K	$21.0K	$84.0K	$139.0K	$410.0K	$-185.0K	$-129.0K	$-355.0K	$-328.0K	$-116.0K	$-1M	$-1M	$-666.0K
Stockholders' Equity	$72M	$88M	$105M	$121M	$141M	$160M	$176M	$198M	$214M	$213M	$238M	$218M	$230M	$261M	$277M	$292M
Liabilities + Equity	$82M	$97M	$117M	$134M	$153M	$171M	$191M	$223M	$238M	$237M	$261M	$242M	$254M	$285M	$301M	$315M
Shares Outstanding	53,460,432	53,331,766	53,331,766	52,993,238	52,993,238	51,954,135	51,935,134	51,749,504	51,522,125	51,445,862	51,157,636	46,143,536	45,774,761	45,624,860	45,622,610	45,532,392

Cash Flow 9

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022
Stock-based Comp	$2M	$1M	$1M	$1M	$2M	$2M	$1M	$2M	$3M	$3M	$3M	$3M	$3M	$2M	$3M	$2M
Operating Cash Flow	$-15M	$-20M	$-17M	$-20M	$-18M	$-18M	$-17M	$-17M	$-2M	$-16M	$-16M	$-13M	$-15M	$-17M	$-14M	$-18M
CapEx	$0	$0	$15.0K	$-1.0K	$11.0K	$4.0K	$56.0K	$1.0K	$4.0K	$594.0K	$44.0K	$565.0K	$156.0K	$2M	$4M	$796.0K
Investing Cash Flow	$-12M	$21M	$18M	$12M	$11M	$29M	$8M	$17M	$2M	$26M	$-34M	$-64M	$50M	$30M	$-15M	$-39M
Stock Issued	·	·	·	·	·	·	·	·	·	·	$33M	·	·	·	·	·
Financing Cash Flow	$143.0K	$0	$392.0K	$0	$103.0K	$10.0K	$172.0K	$0	$141.0K	$0	$33M	$2M	$12.0K	$6.0K	$276.0K	$128.0K
Net Change in Cash	$-27M	$1M	$2M	$-8M	$-7M	$10M	$-9M	$284.0K	$872.0K	$10M	$-16M	$-75M	$35M	$13M	$-29M	$-57M
Taxes Paid	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	$2.0K
Free Cash Flow	·	$-20M	·	·	·	$-18M	·	·	·	$-17M	·	·	$-15M	·	·	$-19M

Profitability 7

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022
Operating Margin	-2396.1%	-1940.7%	·	-1521.8%	-1353.8%	-1114.4%	·	-837.0%	-720.1%	-617.2%	-657.8%	-746.4%	-923.9%	-1723.8%	-2961.1%	-8130.6%
Net Margin	-2295.2%	-1840.6%	·	-1422.9%	-1255.0%	-901.1%	·	-735.2%	-43.3%	-517.3%	-557.6%	-646.7%	-822.7%	-1621.8%	-2865.9%	-8049.3%
Pretax Margin	-2294.8%	-1840.6%	·	-1423.3%	-1254.7%	-1014.6%	·	-732.4%	-620.7%	-517.3%	-557.6%	-646.6%	-822.7%	-1622.6%	-2866.2%	-8048.5%
EBITDA Margin	-2396.1%	-1940.7%	·	-1521.8%	-1353.8%	-1114.4%	·	-837.0%	-720.1%	-617.2%	-657.8%	-746.4%	-923.9%	-1723.8%	-2961.1%	-8130.6%
ROA	-15.4%	-13.5%	·	-11.8%	-10.9%	-8.6%	·	-7.9%	-0.51%	-5.5%	-6.5%	-6.4%	·	-5.8%	-5.3%	-5.5%
ROE	-17.1%	-14.5%	·	-13.2%	-11.9%	-9.3%	·	-8.8%	-0.56%	-6.0%	-7.1%	-7.0%	·	-6.2%	-5.6%	-5.8%
ROIC	-26.4%	·	·	-18.6%	-16.3%	-12.0%	·	-11.1%	-0.66%	·	·	-9.2%	·	-7.4%	-6.5%	-6.4%

Liquidity & Solvency 2

Metric	Trend	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022
Current Ratio		7.7	11.1	·	10.8	12.5	16.8	·	14.0	19.2	16.8	19.2	16.6	·	22.8	24.8	24.7
Quick Ratio		7.5	10.9	·	10.5	12.3	16.4	·	13.5	18.7	16.4	18.8	16.3	·	22.2	24.4	24.2

Efficiency 1

Metric	Trend	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022
Asset Turnover		0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	0.0	0.0	·	0.0	0.0	0.0

Per Share 5

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022
Book Value / Share	$1.34	$1.65	·	$2.28	$2.65	$3.08	·	$3.82	$4.16	$4.13	$4.64	$4.72	·	$5.72	$6.07	$6.41
Revenue / Share	$0.01	$0.02	·	$0.03	$0.03	$0.04	·	$0.05	$0.05	$0.06	$0.06	$0.06	$0.05	$0.02	·	·
Cash Flow / Share	·	$-0.37	·	·	·	$-0.35	·	·	·	$-0.31	·	·	$-0.33	·	·	·
Cash / Share	$0.23	$0.73	·	$0.69	$0.83	$0.99	·	$0.94	$0.94	$0.93	$1.02	$1.48	·	$2.19	$1.91	$2.54
EPS (TTM)	$-1.41	$-1.48	·	$-1.60	$-1.57	$-1.18	·	$-0.99	$-0.96	$-1.32	$-1.56	$-1.62	$-1.62	$-1.59	$-1.52	·

Valuation (TTM) 9

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022
Revenue TTM	$4M	$5M	·	$7M	$9M	$10M	·	$12M	$12M	$12M	$10M	$8M	$6M	$2M	$1M	$550.0K
Net Income TTM	$-75M	$-78M	·	$-83M	$-81M	$-61M	·	$-51M	$-49M	$-65M	$-73M	$-74M	$-74M	$-72M	$-69M	$-65M
Market Cap	$72M	$66M	·	$74M	$56M	$57M	·	$77M	$83M	$87M	$314M	$289M	·	$543M	$650M	$948M
P/E	-1.0	-0.8	·	-0.9	-0.7	-0.9	·	-1.5	-1.7	-1.3	-3.9	-3.9	-2.9	-7.5	-9.4	·
P/S	16.0	12.3	·	10.0	6.6	5.9	·	6.7	7.0	7.4	32.5	37.0	·	263.2	624.5	1723.6
P/B	1.0	0.8	·	0.6	0.4	0.4	·	0.4	0.4	0.4	1.3	1.3	·	2.1	2.3	3.2
P / Tangible Book	1.0	0.8	·	0.6	0.4	0.4	·	0.4	0.4	0.4	1.3	1.3	·	2.1	2.3	3.2
P / Cash Flow	·	-3.4	·	·	·	-3.1	·	·	·	-5.4	·	·	·	·	·	-52.7
Earnings Yield	-105.2%	-119.3%	·	-114.3%	-148.1%	-108.3%	·	-66.4%	-59.3%	-77.6%	-25.4%	-25.9%	-34.0%	-13.4%	-10.7%	·

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Margin %	-1360.4%	-802.0%	-717.3%	-2124.1%	-12982.8%
Net Income	$-78M	$-59M	$-69M	$-73M	$-58M
Diluted EPS	$-1.48	$-1.14	$-1.44	$-1.61	$-1.28

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Current Ratio	10.1	12.2	14.8	22.8	24.7
Quick Ratio	9.9	11.8	14.5	22.3	24.3

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$-74M	$-52M	$-57M	$-72M	$-48M

Institutional owners (13F) 69 filers · $47.1M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 69

Value held $47.1M

New positions 5

Exited positions 8

Institutional activity — Q2 2026 vs prior quarter

New positions	Exited positions	Increased	Decreased	Net shares change
5 (-11 vs prior Q)	8 (0 vs prior Q)	15 (-2 vs prior Q)	22 (+4 vs prior Q)	-2.5M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution	Value	Shares	% of tracked 13F	Type
BML Capital Management, LLC	$7,142,200	5,330,000	15.18%	Shares
TANG CAPITAL MANAGEMENT LLC	$5,688,414	4,245,085	12.09%	Shares
Sio Capital Management, LLC	$3,529,744	2,634,137	7.50%	Shares
Euclidean Capital LLC	$3,521,042	2,627,643	7.48%	Shares
ADAGE CAPITAL PARTNERS GP, L.L.C.	$3,162,400	2,360,000	6.72%	Shares
VANGUARD GROUP INC	$2,712,888	2,170,310	5.77%	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$2,696,107	2,012,020	5.73%	Shares
ArrowMark Colorado Holdings LLC	$2,625,836	1,959,579	5.58%	Shares
TWO SIGMA INVESTMENTS, LP	$2,618,542	1,954,136	5.56%	Shares
Eversept Partners, LP	$2,533,811	1,890,904	5.38%	Shares
BlackRock, Inc.	$1,232,556	919,818	2.62%	Shares
TWO SIGMA ADVISERS, LP	$1,092,625	874,100	2.32%	Shares
Stonepine Capital Management, LLC	$718,355	536,086	1.53%	Shares
GEODE CAPITAL MANAGEMENT, LLC	$634,624	473,158	1.35%	Shares
Aldebaran Capital, LLC	$626,359	467,432	1.33%	Shares
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$574,663	428,853	1.22%	Shares
BIT Capital GmbH	$546,124	407,555	1.16%	Shares
Verdad Advisers, LP	$485,564	362,361	1.03%	Shares
Walleye Capital LLC	$449,830	335,694	0.96%	Shares
Assenagon Asset Management S.A.	$442,204	330,003	0.94%	Shares
MARSHALL WACE, LLP	$430,956	321,610	0.92%	Shares
VANGUARD FIDUCIARY TRUST CO	$341,399	254,775	0.73%	Shares
BANK OF AMERICA CORP /DE/	$321,747	240,110	0.68%	Shares
CITADEL ADVISORS LLC	$271,082	202,300	0.58%	Call option
ADAR1 Capital Management, LLC	$269,351	201,008	0.57%	Shares
STATE STREET CORP	$245,459	183,178	0.52%	Shares
RBF Capital, LLC	$217,348	162,200	0.46%	Shares
GOLDMAN SACHS GROUP INC	$183,572	136,994	0.39%	Shares
MAI Capital Management	$178,383	133,122	0.38%	Shares
Rangeley Capital, LLC	$132,982	99,240	0.28%	Shares
NORTHERN TRUST CORP	$124,683	93,047	0.26%	Shares
Ikarian Capital, LLC	$119,442	89,136	0.25%	Shares
JACOBS LEVY EQUITY MANAGEMENT, INC	$94,475	70,504	0.20%	Shares
PNC Financial Services Group, Inc.	$91,038	67,938	0.19%	Shares
Quadrature Capital Ltd	$83,174	62,070	0.18%	Shares
Seven Fleet Capital Management LP	$71,782	53,569	0.15%	Shares
CITADEL ADVISORS LLC	$63,393	47,308	0.13%	Shares
Accurate Wealth Management, LLC	$62,000	50,000	0.13%	Shares
Cubist Systematic Strategies, LLC	$61,417	43,869	0.13%	Shares
MORGAN STANLEY	$55,856	41,684	0.12%	Shares
JANE STREET GROUP, LLC	$53,878	40,207	0.11%	Shares
ALGERT GLOBAL LLC	$53,403	39,853	0.11%	Shares
COOPER/HAIMS ADVISORS, LLC	$52,288	39,021	0.11%	Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$50,292	37,531	0.11%	Shares
Connor, Clark & Lunn Investment Management Ltd.	$43,496	32,460	0.09%	Shares
Squarepoint Ops LLC	$42,656	31,833	0.09%	Shares
HSBC HOLDINGS PLC	$40,776	30,891	0.09%	Shares
BARCLAYS PLC	$37,201	27,761	0.08%	Shares
BOOTHBAY FUND MANAGEMENT, LLC	$36,349	27,126	0.08%	Shares
Vanguard Global Advisers, LLC	$28,889	21,559	0.06%	Shares

Show all 69 institutional owners →

Activists & 5%+ owners 1 position

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer	Filed	Stake	Status	Purpose	Filing
ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP V LLC ×5 filings	March 4, 2026	0.00%	Amendment	·	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 16 insiders · 5 officers · 9 directors

19

Insider	Role	Last activity	Shares owned	Net 12m
Michael Carulli	Chief Financial Officer	March 5, 2026 A	60,146	$0
Winston Kung	COO, CFO	May 12, 2023 A	10,600	$0
Robert Ticktin	General Counsel & COO	March 5, 2026 A	98,695	$0
Deepika Jalota	Chief Development Officer	March 5, 2026 A	89,959	$0
Leila Alland	Chief Medical Officer	Sept. 15, 2023 S	45,909	$0
Kirsten Flowers	Director	June 4, 2026 A	·	$0
Laurie Stelzer	Director	June 4, 2026 A	·	$0
Charles M Baum	Director	June 4, 2026 A	·	$0
Carol Giltner Gallagher	Director	June 4, 2026 G	·	$0
Arnold J Levine	Director	June 4, 2026 A	409,842	$0
Richard A. Heyman	Director	June 5, 2025 A	0	$0
Peter A. Thompson	Director	June 2, 2022 A	475,000	$0
Thilo Schroeder	Director	Oct. 6, 2021 S	1,101,283	$0
Arnold L Oronsky	Director	Sept. 29, 2020 C	6,469,911	$0
David Henry Mack	·	March 5, 2026 A	451,109	$0
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	·	Sept. 29, 2020 C	760,267	$0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 3 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund	Weight	Units	As of	Source
IWC · iShares Trust	0.02%	159,470 SH	Sept. 11, 2026	Daily
VXF · VANGUARD INDEX FUNDS	0.00%	452,363 SH	Aug. 19, 2026	Daily
VTI · VANGUARD INDEX FUNDS	0.00%	1,487,065 SH	Aug. 19, 2026	Daily

PMVP Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21

rating · 12 analysts BUY

Median target $4.00 +123.5%

4 33.3% Strong Buy

7 58.3% Buy

1 8.3% Hold

0 0.0% Sell

0 0.0% Strong Sell

12-Month Price Target

5 analysts · 2026-09-29

Mean target $4.20 +134.6%

← Below all targets Current price $1.79

Low$3.00 Mean$4.20 High$5.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
PMVP	$67M	-0.8	-40.5%	-1226.8%	-63.4%	·
ABOS	$128M	-1.1	·	·	-129.4%	·
HUMA	·	·	·	·	·	·
KRRO	$75M	-0.6	181.5%	-1834.5%	-140.8%	·
OTLK	$57M	-0.6	·	-4416.2%	193.1%	4.0%
RNA	$10.91B	-14.5	72.1%	-3650.4%	-47.5%	·
CRBU	$151M	-1.0	11.7%	-1327.4%	-102.8%	·
SPRB	$120M	-1.7	-51.3%	·	-139.9%	·
CBUS	·	-0.6	-14.6%	-3492.3%	-223.0%	·
TNYA	$154M	-1.2	·	·	-81.2%	·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

PMVP PMV Pharmaceuticals, Inc. - Common Stock

PMVP Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

PMVP Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Financial Health Debt, liquidity, solvency — balance sheet strength

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Institutional owners (13F) 69 filers · $47.1M total · As of June 30, 2026

Activists & 5%+ owners 1 position

Company insiders 16 insiders · 5 officers · 9 directors

ETF ownership Held by 3 ETFs

PMVP Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

12-Month Price Target

Peer comparison (GICS sub-industry) Key metrics vs sector peers

My Metrics Your personal watchlist — selected rows from Full Fundamentals